Reports show that multiple factors contribute to cancer cell resistance to BET inhibitors [30–33], with c-Myc one of the factors that play a critical role in the resistance to BET inhibitors in pancreatic cancer cells [10, 33, 34]. This evidence concerns the gene MYC and familial pancreatic carcinoma.